Gentaro Ikeda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gentaro Ikeda has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Phillip Chung-Ming Yang
Department of Cardiovascular Medicine, Stanford Medicine, Stanford, CA, United States
4 shared publications Hiroyuki Takashima
Department of Medicine, Division of Cardiovascular Medicine, and Cardiovascular Institute, Stanford University
2 shared publicationsMariko Koike-Ieki
Department of Medicine, Division of Cardiovascular Medicine, and Cardiovascular Institute, Stanford University
2 shared publications- Albert Joseph Rogers
Stanford University
1 shared publication Alyssa Wang
Stanford Cardiovascular Institute, and Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine
1 shared publication- Amogha Paleru
Stanford Cardiovascular Institute, and Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine
1 shared publication
Latest Publications
- Open Access
Feasibility of Noninvasive Atrial and Ventricular Activation, Conduction-Velocity, and Site-of-Origin Mapping with Solid-State Magnetocardiography: A Preclinical Validation Study
Background: Characterizing cardiac activation by its site of origin, propagation, and conduction velocity underlies arrhythmia diagnosis and management, but invasive electrophysiology (EP) mapping requires vascular access, fluoroscopy, and sedation. Magnetocardiography (MCG) enables contactless mapping, and recent solid-state sensors remove the cost, cryogenic, and shielding barriers of legacy systems. We assessed the feasibility of a novel solid-state MCG system for noninvasive arrhythmia site-of-origin (SOO) localization and activation reconstruction, benchmarked against electrocardiographic imaging (ECGi). Methods: In nine swine implanted with right atrial and right ventricular pacing leads, we recorded MCG and ECGi simultaneously during atrial and ventricular pacing. Invasive epicardial contact EP mapping provided the activation-time reference and MRI-derived lead-tip location the SOO reference. Local activation time (LAT), conduction velocity (CV), and SOO were compared on a co-registered chamber mesh. SOO error was the Euclidean distance to the MRI lead tip; LAT and CV agreement with EP were quantified by Pearson r and compared using Wilcoxon signed-rank tests. Results: Across 17 datasets (8 atrial, 9 ventricular), median SOO error was lower for MCG than ECGi in the atrium (19.6 vs 31.2 mm; p=0.023) and ventricle (12.0 vs 26.1 mm; p=0.074). LAT agreement with EP was comparable between modalities and higher in the ventricle (MCG r=0.63; ECGi r=0.68) compared with the atrium (MCG r=0.40; ECGi r=0.53), each correlating with invasive EP mapping above chance. CV agreement was modest and numerically higher for MCG in the ventricle. Conclusions: Solid-state MCG was feasible for noninvasive site-of-origin localization and activation mapping, with accuracy comparable to ECGi, motivating larger prospective studies to define its clinical role in noninvasive mapping. Clinical Perspective: What Is Known: Invasive electrophysiology mapping is the reference standard for localizing the arrhythmia site of origin and characterizing cardiac activation, but it requires vascular access, fluoroscopy, and prolonged sedation within the electrophysiology laboratory. Existing noninvasive options have important limitations: electrocardiographic imaging depends on concomitant thoracic imaging, size-dependent vest fit, and torso-conductivity modeling, while legacy magnetocardiography has required costly cryogenic and magnetically shielded infrastructure. What the Study Adds: In a preclinical large-mammal model referenced to invasive electrophysiology and MRI, a novel contactless solid-state magnetocardiography system feasibly localized atrial and ventricular sites of origin and reconstructed activation without body-surface electrodes. Magnetocardiography localized the site of origin more accurately than ECGi in the atrium, and showed numerically lower localization error in the ventricle. Magnetocardiography displayed activation-time and conduction-velocity agreement with invasive electrophysiology comparable to electrocardiographic imaging in both chambers. Solid-state magnetocardiography may offer a scalable, noninvasive approach for preprocedural localization and complementary activation mapping, motivating larger prospective clinical validation.
Open AccessFeasibility of Noninvasive Atrial and Ventricular Activation, Conduction-Velocity, and Site-of-Origin Mapping with Solid-State Magnetocardiography: A Preclinical Validation Study
Background: Characterizing cardiac activation by its site of origin, propagation, and conduction velocity underlies arrhythmia diagnosis and management, but invasive electrophysiology (EP) mapping requires vascular access, fluoroscopy, and sedation. Magnetocardiography (MCG) enables contactless mapping, and recent solid-state sensors remove the cost, cryogenic, and shielding barriers of legacy systems. We assessed the feasibility of a novel solid-state MCG system for noninvasive arrhythmia site-of-origin (SOO) localization and activation reconstruction, benchmarked against electrocardiographic imaging (ECGi). Methods: In nine swine implanted with right atrial and right ventricular pacing leads, we recorded MCG and ECGi simultaneously during atrial and ventricular pacing. Invasive epicardial contact EP mapping provided the activation-time reference and MRI-derived lead-tip location the SOO reference. Local activation time (LAT), conduction velocity (CV), and SOO were compared on a co-registered chamber mesh. SOO error was the Euclidean distance to the MRI lead tip; LAT and CV agreement with EP were quantified by Pearson r and compared using Wilcoxon signed-rank tests. Results: Across 17 datasets (8 atrial, 9 ventricular), median SOO error was lower for MCG than ECGi in the atrium (19.6 vs 31.2 mm; p=0.023) and ventricle (12.0 vs 26.1 mm; p=0.074). LAT agreement with EP was comparable between modalities and higher in the ventricle (MCG r=0.63; ECGi r=0.68) compared with the atrium (MCG r=0.40; ECGi r=0.53), each correlating with invasive EP mapping above chance. CV agreement was modest and numerically higher for MCG in the ventricle. Conclusions: Solid-state MCG was feasible for noninvasive site-of-origin localization and activation mapping, with accuracy comparable to ECGi, motivating larger prospective studies to define its clinical role in noninvasive mapping. Clinical Perspective: What Is Known: Invasive electrophysiology mapping is the reference standard for localizing the arrhythmia site of origin and characterizing cardiac activation, but it requires vascular access, fluoroscopy, and prolonged sedation within the electrophysiology laboratory. Existing noninvasive options have important limitations: electrocardiographic imaging depends on concomitant thoracic imaging, size-dependent vest fit, and torso-conductivity modeling, while legacy magnetocardiography has required costly cryogenic and magnetically shielded infrastructure. What the Study Adds: In a preclinical large-mammal model referenced to invasive electrophysiology and MRI, a novel contactless solid-state magnetocardiography system feasibly localized atrial and ventricular sites of origin and reconstructed activation without body-surface electrodes. Magnetocardiography localized the site of origin more accurately than ECGi in the atrium, and showed numerically lower localization error in the ventricle. Magnetocardiography displayed activation-time and conduction-velocity agreement with invasive electrophysiology comparable to electrocardiographic imaging in both chambers. Solid-state magnetocardiography may offer a scalable, noninvasive approach for preprocedural localization and complementary activation mapping, motivating larger prospective clinical validation.
- Open Access
- 28 April 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (5)
Plasma Extracellular Vesicle Surface Marker Profiling Reveals Immune Cell–Associated Mitochondrial Membrane Potential Alterations in Long COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
Background: Long COVID (LC) is characterized by symptoms persisting at least 3 months after SARS-CoV-2 infection and affecting multiple organ systems. Diagnosis relies on subjective criteria without established biomarkers. Immune dysregulation and mitochondrial dysfunction are implicated in LC pathophysiology. Given clinical overlap with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), we investigated whether plasma extracellular vesicles (EVs) capture shared molecular signatures. Methods: Plasma EVs from 125 individuals across pandemic-era and prepandemic cohorts were analyzed. The pandemic-era cohort included COVID-Recovered, LC with ME/CFS phenotype (LC-ME/CFS), and ME/CFS without infection (pan-ME/CFS). The prepandemic cohort included ME/CFS and matched controls. Extracellular vesicles were isolated using size-exclusion chromatography. Concentration and size were assessed by nanoparticle tracking analysis, and surface markers and mitochondrial membrane potential were evaluated by flow cytometry. Results: Both pan-ME/CFS and LC-ME/CFS exhibited elevated EV concentrations compared with COVID-recovered controls after false discovery rate (FDR) correction (q = 0.0042 and 0.0024). Leukocyte-, monocyte/macrophage-, and platelet-derived EVs were increased, whereas B cell–derived EVs were reduced in both groups. Compared with controls, pan-ME/CFS demonstrated increased mitochondrial membrane potential in B cell–, monocyte/macrophage-, and NK cell–derived subsets after FDR correction, whereas no significant differences were observed in LC-ME/CFS. Prepandemic ME/CFS showed a nominal increase in leukocyte-derived EVs that did not persist after correction, whereas elevated mitochondrial membrane potential in B cell–derived EV subsets remained significant. Conclusions: ME/CFS and LC-ME/CFS demonstrate partially overlapping immune cell–associated EV alterations. Mitochondrial membrane potential alterations within selected immune-derived EV subsets, particularly B cell–associated EVs, suggest immune-metabolic involvement. Plasma EV profiling may inform future biomarker development.
- 28 April 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (5)
Open AccessPlasma Extracellular Vesicle Surface Marker Profiling Reveals Immune Cell–Associated Mitochondrial Membrane Potential Alterations in Long COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
Background: Long COVID (LC) is characterized by symptoms persisting at least 3 months after SARS-CoV-2 infection and affecting multiple organ systems. Diagnosis relies on subjective criteria without established biomarkers. Immune dysregulation and mitochondrial dysfunction are implicated in LC pathophysiology. Given clinical overlap with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), we investigated whether plasma extracellular vesicles (EVs) capture shared molecular signatures. Methods: Plasma EVs from 125 individuals across pandemic-era and prepandemic cohorts were analyzed. The pandemic-era cohort included COVID-Recovered, LC with ME/CFS phenotype (LC-ME/CFS), and ME/CFS without infection (pan-ME/CFS). The prepandemic cohort included ME/CFS and matched controls. Extracellular vesicles were isolated using size-exclusion chromatography. Concentration and size were assessed by nanoparticle tracking analysis, and surface markers and mitochondrial membrane potential were evaluated by flow cytometry. Results: Both pan-ME/CFS and LC-ME/CFS exhibited elevated EV concentrations compared with COVID-recovered controls after false discovery rate (FDR) correction (q = 0.0042 and 0.0024). Leukocyte-, monocyte/macrophage-, and platelet-derived EVs were increased, whereas B cell–derived EVs were reduced in both groups. Compared with controls, pan-ME/CFS demonstrated increased mitochondrial membrane potential in B cell–, monocyte/macrophage-, and NK cell–derived subsets after FDR correction, whereas no significant differences were observed in LC-ME/CFS. Prepandemic ME/CFS showed a nominal increase in leukocyte-derived EVs that did not persist after correction, whereas elevated mitochondrial membrane potential in B cell–derived EV subsets remained significant. Conclusions: ME/CFS and LC-ME/CFS demonstrate partially overlapping immune cell–associated EV alterations. Mitochondrial membrane potential alterations within selected immune-derived EV subsets, particularly B cell–associated EVs, suggest immune-metabolic involvement. Plasma EV profiling may inform future biomarker development.
- 10 April 2026
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 138 (8) , e326984
Mitochondrial Transfer: From Bench to Bedside
Intercellular mitochondrial transfer has emerged as a fundamental mechanism of tissue adaptation and repair in the cardiovascular system, with major implications for cardiovascular, neurological, metabolic, and inflammatory diseases. Once thought to be static, mitochondria are now recognized as mobile organelles that move between cells via tunneling nanotubes, extracellular vesicles, and free mitochondria. These pathways support 2 complementary axes of mitochondrial communication: Rescue by Replenish, in which healthy mitochondria or mitochondrial components restore bioenergetics and stress resistance in recipient cells, and Relief by Release, in which damaged mitochondria are exported for degradation to preserve homeostasis and limit inflammation. We summarize the molecular machinery governing tunneling nanotube formation, mitochondria-derived vesicle biogenesis, extracellular vesicle sorting, and free mitochondrial release and uptake, and discuss how these processes shape organ function. Building on these mechanistic insights, we outline 4 translational strategies: (1) cell-based therapies that donate healthy mitochondria or scavenge damaged ones; cell-free approaches using (2) mitochondria-containing extracellular vesicles or (3) purified mitochondria; (4) pharmacological, nutritional, and lifestyle interventions that augment endogenous mitochondrial turnover and intercellular exchange. Finally, we discuss key barriers to clinical translation, including inflammatory and oncogenic risks, mitonuclear incompatibility, incomplete understanding of the fate and durability of transferred mitochondria, and the lack of standardized manufacturing, potency assays, and long-term storage methods. Continued integration of mechanistic biology with bioengineering and regulatory science will be essential to safely move mitochondrial transfer–based therapies from bench to bedside in cardiovascular medicine.
- 10 April 2026
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 138 (8) , e326984
Mitochondrial Transfer: From Bench to Bedside
Intercellular mitochondrial transfer has emerged as a fundamental mechanism of tissue adaptation and repair in the cardiovascular system, with major implications for cardiovascular, neurological, metabolic, and inflammatory diseases. Once thought to be static, mitochondria are now recognized as mobile organelles that move between cells via tunneling nanotubes, extracellular vesicles, and free mitochondria. These pathways support 2 complementary axes of mitochondrial communication: Rescue by Replenish, in which healthy mitochondria or mitochondrial components restore bioenergetics and stress resistance in recipient cells, and Relief by Release, in which damaged mitochondria are exported for degradation to preserve homeostasis and limit inflammation. We summarize the molecular machinery governing tunneling nanotube formation, mitochondria-derived vesicle biogenesis, extracellular vesicle sorting, and free mitochondrial release and uptake, and discuss how these processes shape organ function. Building on these mechanistic insights, we outline 4 translational strategies: (1) cell-based therapies that donate healthy mitochondria or scavenge damaged ones; cell-free approaches using (2) mitochondria-containing extracellular vesicles or (3) purified mitochondria; (4) pharmacological, nutritional, and lifestyle interventions that augment endogenous mitochondrial turnover and intercellular exchange. Finally, we discuss key barriers to clinical translation, including inflammatory and oncogenic risks, mitonuclear incompatibility, incomplete understanding of the fate and durability of transferred mitochondria, and the lack of standardized manufacturing, potency assays, and long-term storage methods. Continued integration of mechanistic biology with bioengineering and regulatory science will be essential to safely move mitochondrial transfer–based therapies from bench to bedside in cardiovascular medicine.
- Open Access
- 4 November 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (21) , e037005
Molecular Mechanisms of Exosomes From Human iPSC‐Cardiomyocytes and Mesenchymal Stem Cells in Restoring the Injured Myocardium
Background: Exosomes are extracellular vesicles 30 to 150 nm in size, mediating the paracrine effects of mesenchymal stem cells (MSCs) and induced pluripotent stem cell–derived cardiomyocytes (iCMs) when used to restore the injured myocardium. While both MSC‐ and iCM‐derived exosomes (MSC‐Exo, iCM‐Exo) improve cardiac function, their mechanisms of action remain incompletely understood. This study investigates the shared and distinct effects of iCM‐Exo and MSC‐Exo in a porcine ischemia–reperfusion injury model. Methods: Female Yorkshire swine underwent proximal left anterior descending artery occlusion with a catheter balloon to induce ischemia–reperfusion injury. Ten 500‐μL transendocardial injections delivered a total of 5×10 11 iCM‐Exo or MSC‐Exo into the peri‐infarct region. Cardiac function was assessed via MRI at weeks 2 and 4, while transcriptomic sequencing of peri‐infarct tissue alongside exosomal cargo were performed to elucidate molecular drivers of exosome influenced, post ischemic modulation of gene expression. Results: Cardiac MRI revealed that iCM‐Exo significantly improved left ventricular ejection fraction, myocardial viability, scar size, and ventricular remodeling compared with MSC‐Exo and PBS controls. Transcriptomic analysis revealed both shared and distinct gene expression patterns between the treatments. Shared pathways, including extracellular matrix remodeling and neurovascular integration, contributed to baseline cardiac improvement. Distinct pathways in iCM‐Exo treatment involved metabolic reorganization and cardiomyocyte‐specific processes, while MSC‐Exo emphasized structural stabilization and anti‐inflammatory responses. Conclusions: These findings highlight the complementary roles of iCM‐Exo and MSC‐Exo in myocardial repair with shared pathways contributing to baseline improvement and distinct pathways driving differences in efficacy. Future studies investigating the potential of combinatorial approaches may provide further insights into optimizing the therapeutic outcomes for patients with heart failure.
- 4 November 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (21) , e037005
Open AccessMolecular Mechanisms of Exosomes From Human iPSC‐Cardiomyocytes and Mesenchymal Stem Cells in Restoring the Injured Myocardium
Background: Exosomes are extracellular vesicles 30 to 150 nm in size, mediating the paracrine effects of mesenchymal stem cells (MSCs) and induced pluripotent stem cell–derived cardiomyocytes (iCMs) when used to restore the injured myocardium. While both MSC‐ and iCM‐derived exosomes (MSC‐Exo, iCM‐Exo) improve cardiac function, their mechanisms of action remain incompletely understood. This study investigates the shared and distinct effects of iCM‐Exo and MSC‐Exo in a porcine ischemia–reperfusion injury model. Methods: Female Yorkshire swine underwent proximal left anterior descending artery occlusion with a catheter balloon to induce ischemia–reperfusion injury. Ten 500‐μL transendocardial injections delivered a total of 5×10 11 iCM‐Exo or MSC‐Exo into the peri‐infarct region. Cardiac function was assessed via MRI at weeks 2 and 4, while transcriptomic sequencing of peri‐infarct tissue alongside exosomal cargo were performed to elucidate molecular drivers of exosome influenced, post ischemic modulation of gene expression. Results: Cardiac MRI revealed that iCM‐Exo significantly improved left ventricular ejection fraction, myocardial viability, scar size, and ventricular remodeling compared with MSC‐Exo and PBS controls. Transcriptomic analysis revealed both shared and distinct gene expression patterns between the treatments. Shared pathways, including extracellular matrix remodeling and neurovascular integration, contributed to baseline cardiac improvement. Distinct pathways in iCM‐Exo treatment involved metabolic reorganization and cardiomyocyte‐specific processes, while MSC‐Exo emphasized structural stabilization and anti‐inflammatory responses. Conclusions: These findings highlight the complementary roles of iCM‐Exo and MSC‐Exo in myocardial repair with shared pathways contributing to baseline improvement and distinct pathways driving differences in efficacy. Future studies investigating the potential of combinatorial approaches may provide further insights into optimizing the therapeutic outcomes for patients with heart failure.
- Top Cited PapersOpen Access
- 14 June 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-9
Spinning-enabled wireless amphibious origami millirobot
Wireless millimeter-scale origami robots have recently been explored with great potential for biomedical applications. Existing millimeter-scale origami devices usually require separate geometrical components for locomotion and functions. Additionally, none of them can achieve both on-ground and in-water locomotion. Here we report a magnetically actuated amphibious origami millirobot that integrates capabilities of spinning-enabled multimodal locomotion, delivery of liquid medicine, and cargo transportation with wireless operation. This millirobot takes full advantage of the geometrical features and folding/unfolding capability of Kresling origami, a triangulated hollow cylinder, to fulfill multifunction: its geometrical features are exploited for generating omnidirectional locomotion in various working environments through rolling, flipping, and spinning-induced propulsion; the folding/unfolding is utilized as a pumping mechanism for controlled delivery of liquid medicine; furthermore, the spinning motion provides a sucking mechanism for targeted solid cargo transportation. We anticipate the amphibious origami millirobots can potentially serve as minimally invasive devices for biomedical diagnoses and treatments.
- 14 June 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-9
Top Cited PapersOpen AccessSpinning-enabled wireless amphibious origami millirobot
Wireless millimeter-scale origami robots have recently been explored with great potential for biomedical applications. Existing millimeter-scale origami devices usually require separate geometrical components for locomotion and functions. Additionally, none of them can achieve both on-ground and in-water locomotion. Here we report a magnetically actuated amphibious origami millirobot that integrates capabilities of spinning-enabled multimodal locomotion, delivery of liquid medicine, and cargo transportation with wireless operation. This millirobot takes full advantage of the geometrical features and folding/unfolding capability of Kresling origami, a triangulated hollow cylinder, to fulfill multifunction: its geometrical features are exploited for generating omnidirectional locomotion in various working environments through rolling, flipping, and spinning-induced propulsion; the folding/unfolding is utilized as a pumping mechanism for controlled delivery of liquid medicine; furthermore, the spinning motion provides a sucking mechanism for targeted solid cargo transportation. We anticipate the amphibious origami millirobots can potentially serve as minimally invasive devices for biomedical diagnoses and treatments.
- Open Access
- 15 June 2021
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 10 (12) , e019521
Nanoparticle‐Mediated Simultaneous Targeting of Mitochondrial Injury and Inflammation Attenuates Myocardial Ischemia‐Reperfusion Injury
Background: The opening of mitochondrial permeability transition pore and inflammation cooperatively progress myocardial ischemia‐reperfusion (IR) injury, which hampers therapeutic effects of primary reperfusion therapy for acute myocardial infarction. We examined the therapeutic effects of nanoparticle‐mediated medicine that simultaneously targets mitochondrial permeability transition pore and inflammation during IR injury. Methods and Results: We used mice lacking cyclophilin D (CypD, a key molecule for mitochondrial permeability transition pore opening) and C‐C chemokine receptor 2 and found that CypD contributes to the progression of myocardial IR injury at early time point (30–45 minutes) after reperfusion, whereas C‐C chemokine receptor 2 contributes to IR injury at later time point (45–60 minutes) after reperfusion. Double deficiency of CypD and C‐C chemokine receptor 2 enhanced cardioprotection compared with single deficiency regardless of the durations of ischemia. Deletion of C‐C chemokine receptor 2, but not deletion of CypD, decreased the recruitment of Ly‐6C high monocytes after myocardial IR injury. In CypD‐knockout mice, administration of interleukin‐1β blocking antibody reduced the recruitment of these monocytes. Combined administration of polymeric nanoparticles composed of poly‐lactic/glycolic acid and encapsulating nanoparticles containing cyclosporine A or pitavastatin, which inhibit mitochondrial permeability transition pore opening and monocyte‐mediated inflammation, respectively, augmented the cardioprotection as compared with single administration of nanoparticles containing cyclosporine A or pitavastatin after myocardial IR injury. Conclusions: Nanoparticle‐mediated simultaneous targeting of mitochondrial injury and inflammation could be a novel therapeutic strategy for the treatment of myocardial IR injury.
- 15 June 2021
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 10 (12) , e019521
Open AccessNanoparticle‐Mediated Simultaneous Targeting of Mitochondrial Injury and Inflammation Attenuates Myocardial Ischemia‐Reperfusion Injury
Background: The opening of mitochondrial permeability transition pore and inflammation cooperatively progress myocardial ischemia‐reperfusion (IR) injury, which hampers therapeutic effects of primary reperfusion therapy for acute myocardial infarction. We examined the therapeutic effects of nanoparticle‐mediated medicine that simultaneously targets mitochondrial permeability transition pore and inflammation during IR injury. Methods and Results: We used mice lacking cyclophilin D (CypD, a key molecule for mitochondrial permeability transition pore opening) and C‐C chemokine receptor 2 and found that CypD contributes to the progression of myocardial IR injury at early time point (30–45 minutes) after reperfusion, whereas C‐C chemokine receptor 2 contributes to IR injury at later time point (45–60 minutes) after reperfusion. Double deficiency of CypD and C‐C chemokine receptor 2 enhanced cardioprotection compared with single deficiency regardless of the durations of ischemia. Deletion of C‐C chemokine receptor 2, but not deletion of CypD, decreased the recruitment of Ly‐6C high monocytes after myocardial IR injury. In CypD‐knockout mice, administration of interleukin‐1β blocking antibody reduced the recruitment of these monocytes. Combined administration of polymeric nanoparticles composed of poly‐lactic/glycolic acid and encapsulating nanoparticles containing cyclosporine A or pitavastatin, which inhibit mitochondrial permeability transition pore opening and monocyte‐mediated inflammation, respectively, augmented the cardioprotection as compared with single administration of nanoparticles containing cyclosporine A or pitavastatin after myocardial IR injury. Conclusions: Nanoparticle‐mediated simultaneous targeting of mitochondrial injury and inflammation could be a novel therapeutic strategy for the treatment of myocardial IR injury.